To the full analysis
Bausch + Lomb stock: growth
BLCOBausch + Lomb reported $5.1B in revenue for fiscal 2025, up 6.5% on the prior year, up 8.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.8%
per year from 2018 to 2025, per share 4.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | 8.4% | 4.8% |
| Revenue per share | 8.1% | 4.7% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $3.67B | $710M | $662M |
| 2019 | $3.78B | $298M | $619M |
| 2020 | $3.41B | −$18M | $263M |
| 2021 | $3.77B | $182M | $680M |
| 2022 | $3.77B | $6M | $170M |
| 2023 | $4.15B | −$260M | −$198M |
| 2024 | $4.79B | −$317M | −$59M |
| 2025 | $5.1B | −$360M | −$66M |
Revenue by segment
How Bausch + Lomb Corporation makes its money and how that has shifted. Names are as the company reports them.
- Device Products38%
- Over the Counter Products36%
- Pharmaceutical Products21%
- Branded and Other Generic Products5%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Device Products | $1.65B | $1.8B | $1.92B | 37.7% |
| Over the Counter Products | $1.61B | $1.72B | $1.83B | 36% |
| Pharmaceutical Products | $618M | $969M | $1.08B | 21.2% |
| Branded and Other Generic Products | $252M | $281M | $243M | 4.8% |
| Total revenue | $4.15B | $4.79B | $5.1B | 100% |
Revenue by region
Where Bausch + Lomb Corporation generates its revenue.
- United States and Puerto Rico50%
- China7%
- France5%
- Japan4%
- Germany3%
- Canada3%
- Other29%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| United States and Puerto Rico | $1.7B | $1.93B | $2.41B | $2.55B | 49.9% |
| China | $343M | $344M | $358M | $358M | 7% |
| France | $195M | $210M | $227M | $246M | 4.8% |
| Japan | $192M | $187M | $180M | $186M | 3.6% |
| Germany | $138M | $147M | $152M | $164M | 3.2% |
| Canada | $101M | $110M | $127M | $135M | 2.6% |
| Other | $1.1B | $1.21B | $1.33B | $1.47B | 28.7% |
| Total revenue | $3.77B | $4.15B | $4.79B | $5.1B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.